Pharmacokinetics and Biodistribution of a Human Monoclonal Antibody to Oxidized LDL in Cynomolgus Monkey Using PET Imaging

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Kamath, Amrita V ^a   Williams, Simon P ^a   Bullens, Sherry ^a   Cowan, Kyra J ^a   Stenberg, Yvonne ^b   Cherry, Simon R ^c   Rendig, Stephen ^c   Kukis, David L ^c   Griesemer, Chris ^c   Damico Beyer, Lisa A ^a   Bunting, Stuart ^a  

^a GENENTECH INC   (United States)

^b Bioanalytical and Protein Chemistry   (Sweden)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOTERIC ACID; MONOCLONAL ANTIBODY; N HYDROXYSUCCINIMIDE; OXIDIZED LOW DENSITY LIPOPROTEIN; TETRAXETAN;

ANIMAL EXPERIMENT; ARTICLE; BINDING ASSAY; BONE MARROW; DISTRIBUTION VOLUME; DRUG HALF LIFE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GREAT BLOOD VESSEL; HAPLORHINI; HEART; KIDNEY; LIGAND BINDING; LIMB; LIVER; MALE; NONHUMAN; PATHOGENESIS; PHARMACOKINETICS; POSITRON EMISSION TOMOGRAPHY; SPLEEN; STEADY STATE; TISSUE DISTRIBUTION; TRUNK;

ANIMALS; ANTIBODIES, MONOCLONAL; FEMALE; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; INJECTIONS, INTRAVENOUS; LIPOPROTEINS, LDL; MACACA FASCICULARIS; MALE; POSITRON-EMISSION TOMOGRAPHY; TIME FACTORS; TISSUE DISTRIBUTION;

MACACA FASCICULARIS;

EID: 84866463403     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045116     Document Type: Article

References (13)

1. Hanson GK, (2005) Inflammation, atherosclerosis and coronary artery disease. N Engl J Med 352: 1685-1695.
2. Libby P, Ridker PM, Hansson GK, (2011) Progress and challenges in translating the biology of atherosclerosis. Nature 473: 317-325.
3. Nilsson J, Fredrikson GN, Schiopu A, Shah PK, Jansson B, et al. (2007) Oxidized LDL antibodies in treatment and risk assessment of atherosclerosis and associated cardiovascular disease. Current Pharmaceutical Design 13: 1021-1030.
4. Witztum JL, Steinberg D, (1991) Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 88: 1785-1792.
5. Holvoet P, Harris TB, Tracy RP, Verhamme P, Newman AB, et al. (2003) Association of high coronary heart disease risk status with circulating oxidized LDL in the well-functioning elderly. Findings from the Health, Aging and Body Composition Study. Arterioscler Thromb Vasc Biol 23: 1444-1448.
6. Meisinger C, Baumert J, Khuseyinova N, Loewel H, Koenig W, (2005) Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population. Circulation 112: 651-657.
7. Schiopu A, Frendeus B, Jansson B, Soderberg I, Ljungcrantz I, et al. (2007) Recombinant antibodies to an oxidized low-density lipoprotein epitope induce rapid regression of atherosclerosis in Apobec-1-/-/low-density lipoprotein receptor-/- mice. J Am Coll Cardiol 50(24): 2313-2318.
8. Cheng Z, Xiong Z, Subbarayan M, Chen X, Gambhir SS, (2007) 64Cu-labelled α-melanocyte-stimulating hormone analog for microPET imaging of melanocortin 1 receptor expression. Bioconjug Chem 18: 765-772.
9. Strickland LA, Ross J, Williams S, Ross S, Romero M, et al. (2009) Preclinical evaluation of carcinoembryonic cell adhesion molecule (CEACAM) 6 as potential therapy target for pancreatic adenocarcinoma. J Pathol 218(3): 380-390.
10. Lee JW, Kelley M, King LE, Yang J, Salimi-Moosavi H, et al. (2011) Bioanalytical approaches to quantify "total" and "free" therapeutic antibodies and their targets: technical challenges and PK/PD applications over the course of drug development. AAPS J 13(1): 99-110.
11. Deng R, Iyer.S, Theil FP, Mortensen D, Fielder P, et al. (2011) Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data. mAbs 3(1): 61-66.
12. Hodis HN, Kramsch DM, Avogaro P, Bittolo-Bon G, Cazzolato G, et al. (1994) Biochemical and cytotoxic characteristics of an in vivo circulating oxidized low density lipoprotein (LDL-). J Lipid Res 35(4): 669-77.
13. Hoppin J, Orcutt KD, Hesterman JY, Silva MD, Cheng D, et al. (2011) Assessing antibody pharmacokinetics in mice with in vivo imaging. J Pharmacol Exp Ther 337(2): 350-8.